EPS Holdings, Inc.
EPLYF
Other OTC16.30
USD
- -
- -
EPS Holdings, Inc.
EPLYF
(Other OTC)
Recent
price
16.30
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- EPS Holdings, Inc. (EPLYF) provides comprehensive outsourced solutions to pharmaceutical companies, medical device manufacturers, healthcare ventures, medical institutions, universities, and research organizations primarily in Japan and Asia. The company offers contract research organization (CRO) services including clinical trial planning, management, regulatory submissions, post-marketing surveillance, and early-phase development support; site management organization (SMO) services deploying clinical research coordinators to medical institutions; contract sales organization (CSO) services encompassing medical representative recruitment, training, medical communications, and business process outsourcing such as drug information call centers; incubation business activities involving drug discovery partnerships, investor relations for biotech ventures, external collaborations, and investment; healthcare business development partnering for supplements, cosmetics, and health foods in Japan-China markets; supporting services like human resources, IT systems for clinical trials, non-clinical research product import/export, pharmaceuticals and medical device R&D and manufacturing, human/animal studies, food analysis, and consulting for functional foods; plus shared services, equipment rental, and insurance sales. Founded in 1991 and headquartered in Tokyo, Japan, EPS Holdings operates as a subsidiary of Y&G Limited and leads the EPS Group with over 50 specialized healthcare services across clinical, post-marketing, incubation, and support segments. Recent developments include the October 2024 acquisition of EPS Medical Consultancy (Japan) Co., Ltd. for ¥180 million to bolster consulting capabilities; a May 2024 partnership agreement with Suzuken Group and Bushu Pharmaceuticals to introduce unapproved drugs into Japan; the April 2024 full-scale launch of IRO business to eliminate drug lag/loss and aid foreign biotech market entry; a March 2024 collaboration between EPNextS Group and Frontage Laboratories for U.S. early-phase trials targeting Japan's drug lag issues; and ongoing corporate reorganizations such as the 2024 SMO restructuring.